PROSPECT is an open-label, Phase II study evaluating the efficacy, safety, and pharmacokinetics of an investigational oral medicine called tirabrutinib (ONO-4059), a Bruton’s tyrosine kinase (BTK) inhibitor, in patients with primary central nervous system lymphoma (PCNSL).
This study is actively recruiting. Information about local site coordination is available on clinicaltrials.gov. To learn more about this study, visit https://clinicaltrials.gov/ct2/show/NCT04947319
ONO has a history of tackling challenges: It has overcome difficulties and changes, clearing its own unique path. For more than 300 years since our founding, our enthusiasm and spirit for drug development. We will continue tackling challenges for drug development and have driven creation of innovative new drugs to satisfy people's desire to stay healthy.
INNOVATION Creation of innovative new drugs with researchers around the world in collaboration with Nobel winner researchers who have the world's leading-edge knowledge and technology, we have created 12 prostaglandin products and a cancer immunotherapy. Currently, we are conducting joint research projects with universities, research institutes and biopharmaceutical companies inside and outside Japan.
Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.
